Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report

Journal of Medical Case Reports

Volumn 9, Issue 1, 2015, Pages

  Sevinc, Mustafa ^a   Basturk, Taner ^a   Sahutoglu, Tuncay ^a   Sakaci, Tamer ^a   Koc, Yener ^a   Ahbap, Elbis ^a   Akgol, Cuneyt ^a   Kara, Ekrem ^a   Brocklebank, Vicky ^b   Goodship, Tim H J ^b   Kavanagh, David ^b   Unsal, Abdulkadir ^a  

^a II Ear Nose Throat Head and Neck Surgery   (Turkey)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Complement; Eculizumab; Factor H; Hemolytic uremic syndrome

Indexed keywords

COMPLEMENT FACTOR H; ECULIZUMAB; FRESH FROZEN PLASMA; HAPTOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CLINICAL PRACTICE; DYSPNEA; EXON; FEMALE; FEVER; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; HEADACHE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HIGH TEMPERATURE; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; HYPERVOLEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG CONGESTION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; OPHTHALMOSCOPY; PATHOGENESIS; PERIORBITAL EDEMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TACHYCARDIA; TACHYPNEA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; VEIN COMPLIANCE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GENETICS; MALE; MUTATION; PEDIGREE; PLASMA EXCHANGE; THROMBOTIC MICROANGIOPATHIES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; FEMALE; HUMANS; MALE; MUTATION; PEDIGREE; PLASMA EXCHANGE; RENAL DIALYSIS; THROMBOTIC MICROANGIOPATHIES;

EID: 84928884803     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/s13256-015-0575-y     Document Type: Article

References (18)

1. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508-30.
2. Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol. 2013;56(3):199-212.
3. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-81.
4. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836-44.
5. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(7):2150-5.
6. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-79.
7. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112(13):4948-52.
8. Goicoechea De Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104(1):240-5.
9. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol. 2009;182(11):7009-18.
10. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-62.
11. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-59.
12. Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-67.
13. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8(3), e1001013.
14. Eberhard OK, Labjuhn SO, Olbricht CJ. Ocular involvement in haemolytic uraemic syndrome-case report and review of the literature. Nephrol Dial Transplant. 1995;10(2):266-9.
15. van den Born BJ, van der Hoeven NV, Groot E, Lenting PJ, Meijers JC, Levi M, et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension. 2008;51(4):862-6.
16. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5(4), e10208.
17. Povey H, Vundru R, Junglee N, Jibani M. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. 2014;82(5):326-31.
18. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633-7.